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Clinical experience with Adalimumab in a multicenter Swiss
cohort of patients with Crohn's disease
Abstract
Background: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in
patients with moderate-to-severe Crohn's disease (CD), but there is, however, only limited long-term
experience with adalimumab in daily practice. Aim: To assess the long-term effectiveness and safety of
adalimumab in a multicenter cohort of practice-based patients with moderate-to-severe CD. Methods:
We retrospectively reviewed the charts of CD patients who received adalimumab over a 3-year period.
Disease severity was scored using the Harvey-Bradshaw index (HBI). Remission was defined as an HBI
of </=4 and response as a reduction in the HBI of >3 points at evaluation compared to the baseline.
Univariate logistic regression analysis was used to identify the predictive variables associated with
response. Results: The charts of 55 patients were reviewed; remission and response rates observed at
weeks 4-6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in
89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by
smoking status, disease location or duration, the first month total dose, or previous infliximab therapy.
The remission rate at weeks 4-6 was significantly higher in patients intolerant of infliximab as compared
to those who lost response to this drug. Adalimumab was well tolerated overall. Conclusion:
Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating
sustained long-term effectiveness.
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 Results: The charts of 55 patients were reviewed; remission 
and response rates observed at weeks 4–6 were 52.7 and 
83.6%, respectively. Remission was maintained at weeks 12, 
24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. 
Remission and response rates were not influenced by smok-
ing status, disease location or duration, the first month total 
dose, or previous infliximab therapy. The remission rate at 
weeks 4–6 was significantly higher in patients intolerant of 
infliximab as compared to those who lost response to this 
drug. Adalimumab was well tolerated overall.  Conclusion: 
Adalimumab can be considered a suitable option in patients 
with moderate-to-severe CD, demonstrating sustained long-
term effectiveness.  Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Background: Controlled clinical trials have demonstrated 
the efficacy and safety of adalimumab in patients with mod-
erate-to-severe Crohn’s disease (CD), but there is, however, 
only limited long-term experience with adalimumab in daily 
practice.  Aim: To assess the long-term effectiveness and 
safety of adalimumab in a multicenter cohort of practice-
based patients with moderate-to-severe CD.  Methods: We 
retrospectively reviewed the charts of CD patients who re-
ceived adalimumab over a 3-year period. Disease severity 
was scored using the Harvey-Bradshaw index (HBI). Remis-
sion was defined as an HBI of  ^  4 and response as a reduc-
tion in the HBI of  1 3 points at evaluation compared to the 
baseline. Univariate logistic regression analysis was used to 
identify the predictive variables associated with response. 
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 Introduction 
 Tumor necrosis factor   (TNF-  ) has emerged as a 
central cytokine in the pathogenesis of Crohn’s disease 
(CD), as is confirmed by the central role that TNF-  an-
tagonists now play in the treatment of patients with mod-
erate-to-severe or refractory CD. Infliximab (IFX), the 
first chimeric monoclonal TNF-  antibody, is an effec-
tive treatment for induction and maintenance of remis-
sion in patients with moderate-to-severe CD, including 
those with draining fistulas  [1–4] . However, a proportion 
of patients develop antibodies to IFX, in particular with 
episodic therapy or in the absence of concomitant immu-
nosuppressant medication. The presence of antibodies to 
IFX leads to infusion reactions, loss of response and de-
layed hypersensitivity reactions  [5–7] .
 Adalimumab is a subcutaneously administered re-
combinant, fully human, immunoglobulin G1 monoclo-
nal antibody that binds with high affinity and specificity 
to human TNF. Four pivotal, randomized, double-blind 
trials (CLASSIC-I, CLASSIC-II, CHARM and GAIN) in 
 1 1,400 patients demonstrated the clinical efficacy and 
safety of adalimumab in patients with moderate-to-se-
vere CD  [8–11] . Adalimumab was significantly more ef-
fective than placebo for induction of remission in patients 
naive to anti-TNF therapy (CLASSIC-I trial, 36 vs. 12% at 
week 4 with 160/80 mg regimen, p = 0.004) or in those 
who had either lost responsiveness or developed intoler-
ance to IFX (GAIN trial, 21 vs. 7.2% at week 4, p  ! 0.001). 
The CHARM trial showed that, among patients who re-
sponded to open-label adalimumab induction, mainte-
nance therapy with adalimumab 40 mg weekly or every 
other week for up to 1 year was associated with signifi-
cantly greater remission rates than placebo at weeks 26 
(47, 40 vs. 17%, p  ! 0.001) and 56 (41, 36 and 12%, p  ! 
0.001). In another maintenance trial (CLASSIC-II), pa-
tients who were in remission after a short course of adali-
mumab and who were randomized to receive up to 1 year 
of treatment with adalimumab 40 mg weekly or every 
other week, were significantly more likely to remain in 
remission than those who received placebo (83, 79 vs. 
44%, p  ! 0.05). Loss of efficacy can also be observed with 
adalimumab and an increased dose can be used to restore 
clinical response or remission. The role of antibodies to 
adalimumab in the loss of response is poorly character-
ized to date.
 Adalimumab is generally well tolerated. In clinical tri-
als, the rate of serious adverse events was low in patients 
treated with adalimumab and was similar to those treat-
ed with placebo  [8–11] .
 Patients with CD seen in daily practice may differ 
from the selected patients included in randomized trials 
 [12–15] . In a multicenter open-label single-arm study 
(CARE), adalimumab therapy showed substantial effica-
cy at week 4 (43% remission rate), which was sustained 
through week 20 (52% remission rate), including patients 
who had never responded to IFX  [16] . Neither concomi-
tant steroids nor immunosuppressants notably affected 
the results  [17] . In this study, we analyzed our experience 
with adalimumab in current clinical practice over the 
past 3 years.
 Patients and Methods 
 We performed a retrospective chart review of patients with 
CD who had been treated with adalimumab at the University 
Hospitals of Lausanne, Geneva, Zurich and Olten between April 
2005 and April 2008, and 55 patients who had received adalim-
umab were identified. The diagnosis of CD was confirmed in all 
cases by a review of patients’ medical records including clinical 
notes, endoscopic, radiographic or histological documents.
 The information collected included patient demographics, 
disease location, disease phenotype, disease duration, prior surgi-
cal procedures, smoking status, previous anti-TNF and immuno-
suppressant use, concomitant medication, disease activity at 
baseline and during treatment ( table 1 ). Disease severity for lumi-
nal CD was scored using the Harvey-Bradshaw index (HBI)  [18] . 
For patients with previous surgical resections, other causes of di-
arrhea, such as bile salt malabsorption, small bowel bacterial 
overgrowth, or deficient water absorption secondary to procto-
colectomy, were eliminated before considering them for adalim-
umab therapy.
 The first clinical evaluation was performed at weeks 4–6. Sub-
sequent assessments of the efficacy of treatment were performed 
at weeks 12, 24 and 52. The clinical evolution of luminal CD was 
classified into 3 categories: remission, response, and non-re-
sponse. Remission was defined as an HBI of  ^  4 and response as 
a reduction in the HBI of  6 3 points at the evaluation week com-
pared to the baseline index  [19] . The non-response category in-
cluded all the remaining patients.
 Data on clinical safety were collected at every medical visit and 
the patients were also instructed to contact the physician’s office 
if any illness or adverse reaction occurred. Patients were consid-
ered intolerant to IFX if they were unable to continue the treat-
ment due to reactions judged by the clinician to be linked to the 
perfusion. Loss of responsiveness to IFX was accepted if patients 
did not achieve remission with an increased IFX regimen after 
loss of efficacy at a standard dose.
 We used univariate logistic regression analysis to see if the 
predictive variables tested ( table 2 ,  3 ) were implicated in the re-
sponse rate. The variables which had a p value of  ! 0.3 were tested, 
then together in a multivariate analysis in order to control for the 
confounding effect of each. A p value of  ! 0.05 was considered to 
be statistically significant. Data are expressed according to a per-
protocol analysis. All quantitative variables are expressed as the 
mean  8 standard error.
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 Results 
 This cohort comprised 55 patients (21 men and 34 
women, mean age 37.5  8 11.4 years) treated with adali-
mumab between April 2005 and April 2008. The demo-
graphic data and baseline clinical characteristics are 
summarized in  table 1 . The mean duration of CD was 
12.7 (range 1–41) years. Description of disease location 
of luminal CD followed the usual distribution. One pa-
tient had ileal, colonic and esophageal disease. The 
mean HBI before treatment was 10.9  8 5 points. Twen-
ty-nine patients were smokers. Adalimumab was ad-
ministered to patients intolerant to IFX, to those who 
had lost response to IFX, or to those who were corti-
codependent. Seven patients were treated thus for other 
reasons, 2 of whom had severe spondylarthropathy. The 
indication for adalimumab therapy in the 4 patients 
who had an HBI of  ! 4 points at inclusion was intoler-
ance to IFX (1 patient), lupus-like syndrome with IFX (1 
patient) and corticodependence (2 patients). These pa-
tients were considered to be in remission if their HBI 
remained  ! 4, or were deemed non-responders if their 
HBI value rose during the follow-up period. Of those 
who had already received IFX, 25 patients had episodic 
infusions and 18 patients had regular treatment. All pa-
tients received subcutaneous injections of adalimumab 
at weeks 0 and 2 at a dose of 160/80 mg (31 patients) or 
80/40 mg (24 patients) and then 40 mg every other week. 
The results of detailed subgroup analysis are summa-
rized in  tables 2 and  3 .
 Adalimumab Induces and Maintains Clinical 
Remission and Response in CD Patients 
 At weeks 4–6, in per-protocol analysis, remission had 
been induced in 29 patients (52.7%) and response was 
noted in 46 patients (83.6%). An adalimumab-induced re-
mission was maintained in 26 patients (89.6%) at week 12, 
and in 21 patients (72.4%) at week 24. The evolution over 
time of remission and response rates in per-protocol 
analysis is shown in  figure 1 . However in a intention-to-
treat analysis remission was noticed in 47.3% patients at 
week 24 and in 31% patients at week 52. Response rates at 
the same time points were 54.5 and 34.5%, respectively. 
Thirteen patients (23.6%) required an increase in the 
adalimumab dose: 9 patients to 40 mg every week, 2 pa-
tients to every 10 days, 1 patient to 80 mg every week,
and another to 80 mg every 2 weeks, because of incom-
plete response or loss of response. Of these 13 patients, 6 
(46.1%) achieved remission and another 2 patients re-
sponded. In 1 patient, the dose was reduced to 40 mg ev-
Table 1. Demographic and baseline clinical characteristics (55 pa-
tients)
Patient characteristics n
Gender
Male 21 (38.2%)
Female 34 (61.8%)
Mean age, years 37.5
Disease duration, years
Mean 8 SD 12.67811.4
Range 1–41
Smokers
Yes 29 (52.7%)
No 26 (47.3%)
Disease location (Vienna classification)
L1: Ileal 9 (16.3%)
L2: Colonic 11 (20%)
L3: Ileocolonic 35 (63.6%)
L4: Upper (esophageal) 1 (1.8%)
Disease behavior
(Vienna classification; patients may appear more than once)
B1: non-stricturing non-penetrating 35 (63.6%)
B2: stricturing 7 (12.7%)
B3: penetrating 23 (41.8%)
Surgery for Crohn’s disease
Ileal resection 5 (9%)
Ileocolonic resection 12 (21.8%)
Colonic resection 7 (12.7%)
Proctocolectomy 4 (7.3%)
None 23 (41.8%)
Previous IFX therapy (n = 43)
Side effects 23/43 (53.4%)
Loss of response 19/43 (44.2%)
No/insufficient response 1/43 (2.3%)
Never given 12/55 (21.9%)
Type of IFX therapy
Regular 18/43 (41.9%)
Episodic 25/43 (58.1%)
Concomitant treatment
Budesonide 4 (7.3%)
Prednisone 25 (45.4%)
Azathioprine 5 (9%)
Methotrexate 3 (5.4%)
Indication of adalimumab
Intolerance to IFX 19 (34.5%)
Loss of response to IFX 19 (34.5%)
Corticodependence 10 (18.1%)
Other reasona 7 (12.7%)
Adalimumab induction regimen
160/80 mg 31 (56.4%)
80/40 mg 24 (43.6%)
The values are the number of patients with percentages in pa-
rentheses. IFX = Infliximab.
a Refractory to certolizumab (n = 3), to azathioprine (n = 1), 
extraintestinal manifestations (n = 2), no response to IFX (n = 1).
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Table 2. Response by subgroups at 4–6 weeks
Variable Category Response
n (%)
Nonresponse
n (%) 
Univariate regression Multivariate regression
OR (95% CI) p OR (95% CI) p
Age, years 38.3 33.4 1.04 (0.97–1.12) 0.249 1.04 (0.97–1.12) 0.268
Gender Female 29 (85.3%) 5 (14.7%) 1
Male 17 (80.9%) 4 (20.1%) 0.73 (0.17–3.10) 0.673
Smoking status Non-smoker 23 (88.5%) 3 (11.4%) 1
Smoker 23 (79.3%) 6 (20.7%) 0.50 (0.11–2.24) 0.366
Disease duration, 
years
<7 15 (83%) 3 (17%) 1
<7–15 16 (84%) 3 (17%) 1.00 (0.17–5.72) 1
>15 15 (83%) 3 (17%) 0.94 (0.16–5.39) 0.942
Disease location Ileitis (L1) 8 (80%) 2 (20%) 1
Colitis (L2) 10 (91%) 1 (9%) 2.22 (0.17–8.86) 0.542
Ileocolitis (L3) 28 (82.3%) 6 (17.3%) 1.04 (0.19–6.07) 0.968
Previous resection
(any segment)
No 18 (78.3%) 5 (21.7%) 1
Yes 28 (87.5%) 4 (12.5%) 1.94 (0.46–8.22) 0.366
Previous IFX
therapy
Never 9 (75%) 3 (25%) 1
Episodic 21 (84%) 4 (16%) 1.57 (0.29–8.41) 0.595
Regular 16 (88.9%) 2 (10.1%) 2.40 (0.34–6.97) 0.380
Indication for
adalimumab
Loss of response to IFX 17 (89.4%) 2 (10.6%) 1 1
Intolerance to IFX 17 (89.4%) 2 (10.6%) 0.94 (0.12–7.48) 0.957 1
Othera 12 (70.5%) 5 (20.5%) 0.27 (0.04–1.61) 0.149 0.33 (0.07–1.68) 0.182
First-month total 
dose, mg
120 (80+40) 19 (79.2%) 5 (21%) 1
240 (160+80) 27 (87.1%) 4 (13%) 1.00 (0.99–1.02) 0.434
First-month total 
dose/weight, mg/kg
<2.5 17 (80.9%) 4 (19.1%) 1 1
2.5–3.5 13 (76.4%) 4 (23.6%) 0.72 (0.15–3.43) 0.682 1
>3.5 16 (94.1%) 1 (5.9%) 3.56 (0.36–5.20) 0.278 3.87 (0.38–39.03) 0.251
IFX = Infliximab. a Corticodependence (n = 10) and other (n = 7) merged because of small numbers.
Table 3. Remission by subgroups at 4–6 weeks
Variable Category Remission
n
Non-remission
n
p value
Smoker status Smoker 12 (41.4%) 17 (58.6%) 0.075
Non-smoker 17 (65.4%) 9 (34.6%)
Previous IFX
therapy
Regular 10 (55.5%) 8 (44.5%) 0.719
Episodic 12 (48%) 13 (52%)
Never 7 (58.3%) 5 (41.7%)
Indication for adalimumab Loss of response to IFX 8 (42.1%) 11 (57.9%) 0.012
Intolerance to IFX 15 (78.9%) 4 (21.1%)
IFX = Infliximab.
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ery 4 weeks because of fatigue. The response rate was not 
significantly higher in the group of patients with previ-
ous abdominal surgery ( table 2 ).
 Effect of Smoking on Adalimumab Efficacy at
Weeks 4–6 
 The remission and response rates were higher among 
the non-smokers, but without any statistically significant 
difference.
 Effect of Disease Duration or Location on 
Adalimumab Efficacy at Weeks 4–6 
 Because of the long mean disease duration of our co-
hort, we chose to separate the patients into 3 almost equal 
groups: CD known for  ! 7 years, for 7–15 years and for 
 1 15 years. The remission and response rates were almost 
similar within these 3 groups. The location of the intes-
tinal segment(s) involved was not found to play a signifi-
cant role in patients’ clinical response to the adalimumab 
therapy.
 Effect of the First-Month Total Dose on Adalimumab 
Efficacy at Weeks 4–6 
 Remission and response rates were not different be-
tween the groups who received adalimumab 240 or 120 
mg during the first month of treatment. The total first-
month adalimumab dose was divided by the patient’s 
weight and patients were then grouped into 3 dose-ad-
justed groups according to the total dose per kilogram 
over the first month:  ! 2.5, 2.5–3.5 and  1 3.5 mg/kg. We 
did not find any statistically significant difference be-
tween these 3 groups with regard to the response rate.
 Impact of Prior IFX Treatment on Adalimumab 
Efficacy at Weeks 4–6 
 The response rate was not influenced by the absence 
of previous IFX treatment or by its regular as opposed to 
episodic use. In contrast, the remission rate at weeks 4–6 
was significantly higher among patients intolerant to 
IFX, compared to those who had lost response to this 
medication (78.9 vs. 42.1%, p = 0.02).
 Safety of Adalimumab Treatment 
 Overall, subcutaneous injections of adalimumab 
were well tolerated ( table 4 ). Thirty of the 55 patients 
reported no adverse event. The most common side effect 
was pain at the injection site (10.9%), followed by asthe-
nia (9%) and infections (7.2%). One patient stopped the 
treatment because of intolerable fatigue and another be-
cause of gynecological side effects. One case of lupus-
like syndrome was noted. In our cohort, no fatal com-
plication, malignancy, neurologic or cardiovascular 
complication was noted during the whole observation 
period.
0
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No response/stop
Time, weeks
%
 Fig. 1. Response and remission rate over time in per-protocol 
analysis. 
Table 4. Adverse events observed over the 3-year period
Type of adverse event n
None 30
Perianal abscesses 2
Asthenia 5
Pain at injection site 6
Pruritis at injection site 2
Rash 1
Headache 3
Nausea 2
Diarrhea 1
Dizziness 2
Phlebitis 1
Gynecological side effect 1
Labial herpes 1
Lupus-like syndrome 1
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 Discussion 
 The purpose of our retrospective cohort study was to 
evaluate the effectiveness of adalimumab in our Crohn’s 
patients over a period of 3 years in daily clinical practice. 
Adalimumab treatment was effective in the induction and 
maintenance of remission in patients with moderate-to-
severe CD. The results in our cohort appear better than the 
remission and response rates noticed in the CLASSIC I 
trial (36 and 59%, respectively, at week 4)  [8] and the GAIN 
trial (21 and 52%, respectively, at week 4)  [11] . The fact that 
in our cohort the first evaluation occurred later than in 
those trials, i.e. that our patients had a supplementary 
third injection, may have contributed to the improved re-
sults. In the per-protocol analysis, 44.7% patients were in 
remission and 50% still in response at week 52. These long-
term results for remission are similar to those at week 56 
in the CLASSIC II trial  [9] . The limited size of our cohort, 
the lack of placebo controls and the absence of restricted 
inclusion criteria may have contributed to the differences 
noticed in our patients. In addition, we used the HBI rath-
er than the Crohn’s Disease Activity Index to evaluate pa-
tients, which could also in part explain the difference from 
the randomized trial. The remission and response rates in 
our cohort are also comparable to those of the CARE study 
 [16, 17] , although in this multicenter cohort all patients 
received a 160/80-mg induction regimen.
 The proportion of our patients who needed a dose in-
crease and the benefit obtained from this strategy were 
similar to those reported in the CHARM trial  [20] . In our 
cohort, the mean time to dose increase was relatively 
long: 7 (range 1–24) months. Our results thus confirm 
that in clinical practice this strategy should be explored 
before considering another treatment in patients who 
lose response or fail to achieve complete remission with a 
standard adalimumab regimen. In a small study, a higher 
percentage of patients were previously reported to require 
an adalimumab dose increase (nearly 60% at 6 months) 
after using a suboptimal induction regimen of 80/40 mg 
 [12] . In another 2 cohorts, only 13.2 and 29% of patients 
required a dose increase  [14, 15] .
 In a per-protocol analysis, we observed that over 52 
weeks adalimumab treatment was stopped in half of the 
patients. This dropout rate was progressive during the 
observation period. The reasons for discontinuation were 
either no response, loss of response despite dose increase 
(14/19 patients) or adverse reaction (5/19 patients).
 Smoking status had no effect on either the rate of clin-
ical remission or the response rate in patients treated with 
adalimumab. This observation is consistent with the re-
sults of the sub-analysis in the CLASSIC I trial, where the 
efficacy of adalimumab treatment at week 4 was not af-
fected by smoking status  [21] . Hinojosa et al.  [13] also re-
ported no difference in the 4-week response rate of active 
smokers with luminal CD as compared to former smok-
ers.
 The efficacy of adalimumab therapy in our cohort was 
not influenced by disease duration. In the CHARM trial, 
Colombel et al.  [10] showed a significantly better remis-
sion rate at weeks 26 and 56 with adalimumab in patients 
with a CD duration of  ! 2 or  1 5 years. We were unable to 
separate our patients into the same 3 groups (disease du-
ration  ! 2, 2–5 and  1 5 years) because our patients had a 
longstanding diagnosis of CD. Our results suggest that a 
disease duration of  1 7 years has no greater impact on re-
sponse.
 We failed to show a correlation between the total first 
month dose adapted to body weight or the response or 
remission rate to adalimumab therapy. These results sug-
gest that the dose during the first month as currently ad-
ministered should suffice in the majority of patients. 
However, the small size of the cohort and the retrospec-
tive nature of the analysis do not exclude the possibility 
that a dose-weight relationship might exist in a larger 
group of patients. Indeed, as the affinities and molecular 
weight of IFX and adalimumab are comparable, one 
could have expected that such a relationship might exist. 
Other characteristics of adalimumab may explain this 
difference as compared to IFX, such as the human nature 
of the antibody or differences in the binding sites of the 
antibodies.
 The majority of our patients had been treated with IFX 
before receiving adalimumab. The remission and re-
sponse rates at weeks 4–6 were not statistically different 
in patients naive to IFX compared to those who had al-
ready been treated with IFX. Similarly, no difference was 
found in the response to adalimumab between patients 
whose previous IFX therapy was interrupted because of 
loss of response or because of intolerance. This last obser-
vation was also reported by Hinojosa et al.  [13] . In con-
trast, however, the remission rate at weeks 4–6 was sig-
nificantly higher in the subgroup of patients intolerant to 
IFX. This suggests that patients who did not lose their 
response to IFX may benefit more from another anti-TNF 
agent. Patients who have lost response may represent a 
group of patients who may better benefit from a change 
in the treatment target, different from TNF.
 Overall, adalimumab was well tolerated in our cohort. 
The rate of side effects was similar to that already report-
ed in randomized trials, in which patients underwent 
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more stringent selection and monitoring  [8–10] . Pain at 
the injection site, asthenia and infections were the most 
common adverse events. Despite these reassuring results, 
the safety issues surrounding anti-TNF therapies contin-
ue to be of great significance and clinicians need to re-
main vigilant. Colombel et al.  [22] recently assessed glob-
al adalimumab safety in a collective of 2,228 patients ex-
posed to adalimumab in pivotal randomized trials, 
open-label extensions and phase IIIb studies, CHOICE 
and CARE. The rates of opportunistic infections and ma-
lignant neoplasms were found to be  ! 2% of patients. Such 
rates justify careful monitoring of all patients, even when 
stable in remission.
 Our study has several limitations. Firstly, the data pre-
sented are based on a retrospective review and not on a 
uniform analysis with precise time points. Secondly, even 
if this is the largest cohort of open-label clinical experi-
ence in patients with CD to date, the number of patients 
analyzed at 24 and 52 weeks is still low. Thirdly, our pa-
tients had a long-standing CD history prior to adalim-
umab therapy. It remains to be studied if adalimumab 
used in a top-down scheme might improve the results re-
ported here. Although nonsignificant, the odds ratio val-
ues cannot be taken as proof that none of the variables 
mentioned in  table 2 may have an effect. The large confi-
dence intervals indicate that the calculated odds ratio re-
mains imprecise.
 In conclusion, our data suggest that adalimumab is as 
effective in inducing and maintaining remission in pa-
tients with moderate-to-severe or refractory CD seen in 
daily practice as reported during randomized trials. Our 
results further suggest that patients with intolerance to 
IFX represent a group particularly well suited to further 
adalimumab therapy. The safety of adalimumab is also 
confirmed in daily practice. However, results from larger 
cohorts should be awaited before reaching firm conclu-
sions.
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